BRCA1 Inactivation Detection via Chromosomal Break Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting BRCA1 inactivation in basal-like breast carcinomas and other cancers are inadequate, as they either focus on chromosomal breaks leading to telomeric allelic imbalance or loss of heterozygosity, failing to account for chromosomal breakpoints and rearrangements, which impairs their robustness and accuracy.
Innovation Solution
A method that quantifies large-scale chromosome breaks in genomic DNA, specifically focusing on rearrangements resulting in segments of at least 3 megabases, to predict Homologous Recombination (HR) deficiency, which is strongly indicative of BRCA1 inactivation, and uses this information to determine the efficacy of treatments involving PARP inhibitors and alkylating agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods focus on chromosomal breaks leading to telomeric allelic imbalance or loss of heterozygosity, then detection of HR deficiency is attempted, but accuracy and robustness deteriorate due to failure to account for chromosomal breakpoints and rearrangements
Solution Approach 1:
The patent segments the analysis of chromosomal abnormalities into distinct components: telomeric allelic imbalance, loss of heterozygosity, and chromosomal breakpoints/rearrangements. By separately evaluating each segment and integrating their results, the method achieves more comprehensive and accurate prediction of HR deficiency while maintaining robustness across different tumor types.
Solution Approach 2:
The patent develops a multi-functional prediction method that can universally detect HR deficiency across different cancer types (breast, ovarian, and other carcinomas) by integrating multiple genomic markers. This universal approach maintains high accuracy and robustness regardless of the specific tumor type or mechanism of BRCA1 inactivation.
2Ease of operation
If methods only consider telomeric allelic imbalance, then detection simplicity is maintained, but prediction accuracy deteriorates due to exclusion of other chromosomal break mechanisms
Solution Approach 1:
The patent divides the detection process into separate analytical segments for different genomic markers (telomeric allelic imbalance, loss of heterozygosity, chromosomal breakpoints). Each segment can be evaluated independently using established techniques, maintaining operational simplicity while collectively providing comprehensive prediction accuracy.
Solution Approach 2:
The patent merges multiple detection approaches by integrating results from telomeric allelic imbalance analysis, loss of heterozygosity detection, and chromosomal breakpoint identification. This combination maintains the simplicity of individual methods while achieving superior overall prediction accuracy through synergistic integration.
3Measurement precision
If comprehensive genomic analysis including all chromosomal rearrangements is performed, then prediction accuracy of HR deficiency improves, but method complexity increases
Solution Approach 1:
The patent segments comprehensive genomic analysis into manageable components: array-CGH for copy number variations, SNP arrays for loss of heterozygosity, and specific algorithms for identifying chromosomal breakpoints. This segmentation enables systematic processing of complex data while maintaining high prediction accuracy through structured analysis.
Solution Approach 2:
The patent introduces computational algorithms and bioinformatics tools as intermediaries to process and integrate complex genomic data from multiple sources. These intermediary systems automatically synthesize information from array-CGH, SNP arrays, and other platforms, reducing manual complexity while preserving comprehensive prediction accuracy.
Data Source
AI summary
The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.